Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 16

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 16
---
 $139,328 for the three months ended June 30, 2025 and 2024, respectively.
These expenses were recorded as stock compensation included in payroll and related expenses in the accompanying consolidated statement
of operations for the three months ended June 30, 2025 and 2024.

The table below summarizes restricted stock units
as of June 30, 2024 and changes during the three months ended June 30, 2025.

    Schedule of RSUs 

    Shares 
  
    Nonvested RSUs at April 1, 2025 
     – 
  
    Granted 
     71,432 
  
    Vested 
     (13,393)
  
    Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units 
     (4,465)
  
    Nonvested RSUs at June 30, 2025 
     53,574 

Our total stock-based compensation for the three months
ended June 30, 2025 and 2024 included the following:

    Schedule of stock-based compensation 

    Three Months Ended 

    June 30, 2025  
    June 30, 2024 
  
    Vesting of restricted stock units 
    $50,000  
    $68,750 
  
    Vesting of stock options 
     22,442  
     70,578 
  
    Total Stock-Based Compensation 
    $72,442  
    $139,328 

     14 

We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting
the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the three months ended June 30, 2024 was insignificant.

On June 30, 2025, our outstanding stock options had
no intrinsic value since the closing price on that date of $1.20 per share was below the weighted average exercise price of our outstanding
stock options.

At June 30, 2025, there was approximately $206,106
of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of
.71 years.

9. WARRANTS

We did not issue any warrants in the three-months
ended June 30, 2025. We issued